[Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005712:Galvanic Skin Response / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010919:Placebos; D012119:Respiration / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced
D006834:Hydrazines; D010919:Placebos; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
Wirkung eines Decarboxylasehemmers (Ro 4-4602) in Kombination mit L-DOPA auf gehemmte Depressionen.